Aptevo Therapeutics Inc. reported financial results for the year ended December 31, 2025.
“On March 26, 2026, Aptevo Therapeutics Inc. (the “Company”) issued a press release announcing its financial results for the period ended December 31, 2025.”
Aptevo Therapeutics Inc. — fact timeline
Source-grounded facts extracted from Aptevo Therapeutics Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Aptevo Therapeutics Inc. entered into Standby Equity Purchase Agreement with YA II PN, LTD. valued at up to $60.0 million (effective 2026-01-08).
“On January 8, 2026, Aptevo Therapeutics Inc. (the "Company") entered into a Standby Equity Purchase Agreement (the "Purchase Agreement") with YA II PN, LTD., a Cayman Islands exempt limited company ("Yorkville"). Pursuant to the Purchase Agreement, the Company has the right, but not the obligation, to issue and sell to Yorkville from time to time (each such occurrence, an "Advance") up to $60.0 million (the "Commitment Amount") of the Company's common stock”
Aptevo Therapeutics Inc.: Amendment to Certificate of Incorporation to effect a 1-for-18 reverse stock split (effective 2025-12-29).
“Accordingly, on December 29, 2025, the Company filed a Certificate of Amendment of Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effect the Reverse Stock Split. The Amendment was effective at 5:01 p.m. Eastern Time on December 29, 2025 (the “Effective Time”).”
Aptevo Therapeutics Inc. engaged Baker Tilly US, LLP as its auditor.
“the Audit Committee of the Company’s Board of Directors approved the appointment of Baker Tilly, as the successor to Moss Adams, as the Company’s independent registered public accounting firm for the year ending December 31, 2025”
Moss Adams LLP resigned as auditor of Aptevo Therapeutics Inc..
“On June 23, 2025, Aptevo Therapeutics Inc., (the "Company") was notified that Moss Adams LLP ("Moss Adams"), the Company's independent registered public accounting firm, merged with Baker Tilly US, LLP effective on June 3, 2025.”
Aptevo Therapeutics Inc. reported the quarter ended March 31, 2024 results: net income a net loss of $6.8 million or $9.95 per share, EPS $9.95 per share.
“Aptevo Therapeutics Inc. (Nasdaq: APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIRTM and ADAPTIR-FLEXTM platform technologies, today reported financial results for the quarter ended March 31, 2024 and provided a business update.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.